02219 CHAOJU EYE CARE
- 3.930
- +0.050+1.29%
CHAOJU EYE CARE News
Chaoju Ophthalmology (02219.HK): Strong mergers and acquisitions in basic consumer ophthalmology combine rapid expansion
Chaoju Ophthalmology (2219.HK): Looking forward to steady revenue growth in 24 years
Chaoju Ophthalmology (02219.HK): Performance is basically in line with expectations, and the store network continues to expand
Chaoju Ophthalmology (2219.HK) 2023 Annual Performance Report Review: Basic Consumer Ophthalmology Dual Growth Mergers and Acquisitions New Hospitals Dual Drivers
Chaoju Ophthalmology (2219.HK): Strong growth in basic consumer ophthalmology, new hospitals continue to climb
Chaoju Ophthalmology (2219.HK): North China's leading ophthalmology medical leader promotes endogenous epitaxial growth
Review of Chaoju Ophthalmology (2219.HK) Interim Report: Post-epidemic recovery performance is obvious, and basic consumer ophthalmology has both increased
Chaoju Ophthalmology (02219.HK) 2023 Interim Report Review: Business Recovery Is Clearly Rooted in North China and the Yangtze River Delta
Chaoju Ophthalmology (02219.HK): 1H23 performance is in line with expectations and profitability is gradually improving
Chaoju Ophthalmology (2219.HK) Company Review: Performance Recovery, Profitability, and Steady Progress in Strategic Expansion
Chaoju Ophthalmology (02219.HK): Deeply involved in North China radiating both internal and external training in Jiangsu and Zhejiang, with outstanding profits
Chaoju Ophthalmology (2219.HK): Fundamentals are firmly looking forward to a steady recovery in 23 years
Chaoju Ophthalmology (2219.HK): Results in '22 are under pressure and we are optimistic about the return of patients in '23
Big Bank Ratings | CICC: For the first time, Chaoju Ophthalmology's target price of “outperforms the industry” rating is HK$7.68
Chaoju Ophthalmology (2219.HK): The growth of the ophthalmology industry determines the expansion of endogenous epitaxial expansion
Chaoju Ophthalmology Clinic (2219.HK) first coverage: deepening expansion outside of Inner Mongolia
Chaoju Ophthalmology (2219.HK): Mergers and acquisitions are imminent in North China
Chaoju Ophthalmology Clinic (2219.HK): The number of patients affected by the epidemic may accelerate 2H22
Chaoju Ophthalmology (02219.HK): Profitable regional ophthalmology leaders can be expected in the future
Chaoju Ophthalmology (02219.HK): Clustered Operation Creates a Competitive Advantage Consumes Ophthalmology Nuggets
Analysis
Price Target
No Data
